Boehringer Enters Asthma Market With New Indication For Spiriva Respimat
Executive Summary
Spiriva – the first long-acting muscarinic antagonist approved for asthma – wins broad indication; sales target is likely sizeable patient population with uncontrolled disease.
You may also be interested in...
FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.